Comparative Pharmacology
Head-to-head clinical analysis: APRACLONIDINE HYDROCHLORIDE versus IOPIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APRACLONIDINE HYDROCHLORIDE versus IOPIDINE.
APRACLONIDINE HYDROCHLORIDE vs IOPIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alpha-2 adrenergic receptor agonist; reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
Alpha-2 adrenergic agonist; reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
1-2 drops of 0.5% or 1% solution in the affected eye(s) three times daily.
Adults: 1 drop of 0.5% or 1% ophthalmic solution in the affected eye(s) three times daily, beginning 48 hours prior to surgery and continuing on the day of surgery. Alternatively, for intraocular surgery, 1 drop of 1% solution is administered 1 hour before surgery and 1 drop immediately after surgery.
None Documented
None Documented
Terminal elimination half-life is 8.0-12.0 hours (mean 10 h) in normal renal function; prolonged to up to 40 hours in severe renal impairment.
0.5-2 hours (terminal) for topical ophthalmic administration; clinical effect may persist longer due to local tissue binding.
Renal excretion: approximately 40% unchanged; hepatic metabolism (CYP2D6) with biliary/fecal elimination of metabolites; total clearance 0.15 L/h/kg.
Renal excretion (% unchanged drug not determined; metabolites excreted renally)
Category A/B
Category C
Alpha-2 Agonist
Alpha-2 Agonist